Browse by Series:

Full FDA Approvals in Breast Cancer and Lung Cancer, Priority Reviews in ALL, and More

Brielle Urciuoli
Published: Thursday, Apr 06, 2017



Brielle Urciuoli reports on full FDA approvals in breast cancer and non–small cell lung cancer, priority reviews in acute lymphoblastic leukemia, an ODAC recommendation for hematologic malignancies, a biologics license application submitted in non–Hodgkin lymphoma, a new drug application accepted in graft-versus-host disease, promising phase III results and a European approval in lung cancer.
SELECTED
LANGUAGE
Slider Left
Slider Right


Brielle Urciuoli reports on full FDA approvals in breast cancer and non–small cell lung cancer, priority reviews in acute lymphoblastic leukemia, an ODAC recommendation for hematologic malignancies, a biologics license application submitted in non–Hodgkin lymphoma, a new drug application accepted in graft-versus-host disease, promising phase III results and a European approval in lung cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x